Spin offs

<p>Logo Nostrum Biodiscovery</p>

Nostrum Biodiscovery is a biotechnological company focused on the computational biology sector and, specifically, in the structure-based drug design area dedicated to early drug discovery and development based on rational design techniques.

Inbiomotion is a Barcelona-based personalized medicine company incorporated in 2011 with the goal of developing biomarkers that predict bone metastasis to improve the cancer patient’s quality of life.

Iproteos is a biotechnology company focused on the research and development of third-generation drugs based on peptidomimetics for human diseases. The company’s strategy is based on peptidomimetics, molecules able to modulate the activity of undruggable targets, such as Protein-Protein Interactions (PPIs).

Innovation projects

IRB Barcelona Spin offs

Innovation projects

The Innovation Department is an accredited TECNIO agent in the category of Developers and Technology Enablers.

The TECNIO seal is awarded by the Government of Catalonia, through ACCIÓ, and identifies key technology providers and facilitators in Catalonia. This seal supports the most qualified agents involved in technology transfer; allows companies to access advanced R&D to develop new products and services; increases the scope of technology projects by finding the most suitable technology partners & suppliers; and helps raise competitiveness and technological innovation capacities.

VALUNI 2016 aims to promote the commercialization of projects and technologies by supporting key activities that facilitate the licensing of patents and/or creation of technology-based companies. Two projects promoted by the Innovation Department were awarded in 2017: “Colostage Technology” and “Gate2Brain – transport de molècules al cervell”.

Gínjol is a new patent fund set up by CERCA, an organization belonging to the Government of Catalonia that supervises, supports and facilitates the activities of research centres in Catalonia. IRB Barcelona received funding for the two projects submitted by Innovation Department in the first call for application launched at the end of 2016. Two patents at IRB Barcelona were awarded in the first Gínjol call: “Oncoselective mechanism for gene or viral therapy”, and “A novel and promising new target against Alzheimer’s disease".


<p>Mouse cells with DOR protein. (M. Romero, IRB Barcelona)</p>
19 Abr 2018

L'obesitat és considerada com un problema de salut mundial perquè l'acumulació excessiva de greix (teixit adipós) incrementa el risc de patir malalties cardiovasculars, hipertensió, diabetis i algu

<p>Illustrative image of how scientists have deciphered the covalent nature of beta-amyloid dimers, an article published in Analytical Chemistry. Authors: Marina Gay, IRB Barcelona, and Lorena Markovich</p>
17 Abr 2018

A dia d’avui, els dos biomarcadors més ben establerts per diagnosticar precoçment l’Alzheimer són la concentració de la proteïna beta-amiloide i de proteïna tau fosforilada en líqu

<p>Image: University of Barcelona</p>
13 Abr 2018

Un equip científic ha descrit per primer cop l’acció sinèrgica in vivo dels transportadors d’aminoàcids neutres LAT2 i TAT1 i la seva participació en el procés de reabsorció renal.

<p>Francesc Posas, new director of IRB Barcelona</p>
12 Abr 2018

Francesc Posas Garriga, investigador de referència internacional en biologia cel·lular i catedràtic de la Universitat Pompeu Fabra (UPF), serà el nou director de l’Institut de Rece



Cristina Horcajada
Head of Innovation
Tel: +34 93 40 31193
  • Tecnio Catalonia